Clinical Epidemiology and Antimicrobial Susceptibility of Carbapenemase-Producing Enterobacterales from a German University Hospital During a 5-Year Period.

IF 1.9 4区医学 Q3 INFECTIOUS DISEASES

Microbial drug resistance Pub Date : 2025-09-30 DOI:10.1177/10766294251384459

Julius Sommer, Jan Esse, Jürgen Held, Sven Voigtländer, Christian Bogdan, Giuseppe Valenza

{"title":"Clinical Epidemiology and Antimicrobial Susceptibility of Carbapenemase-Producing Enterobacterales from a German University Hospital During a 5-Year Period.","authors":"Julius Sommer, Jan Esse, Jürgen Held, Sven Voigtländer, Christian Bogdan, Giuseppe Valenza","doi":"10.1177/10766294251384459","DOIUrl":null,"url":null,"abstract":"The primary purpose of this study was to assess the prevalence and the antimicrobial susceptibility rates of carbapenemase-producing Enterobacterales (CPE) in a German University Hospital during a 5-year period. From January 2020 to December 2024, all Enterobacterales detected were molecularly investigated for carbapenemases in every case of elevated minimum inhibitory concentration of ertapenem, meropenem, or imipenem. Subsequently, CPE were tested for susceptibility to reserve antibiotics. Overall, 101 CPE were identified. Most of the CPE strains harbored only one carbapenemase gene, such as blaOXA-48 (n = 32, 31.6%), blaNDM (n = 27, 26.7%), and blaVIM (n = 14, 13.8%). The annual number of CPE detected increased during the observation period (2020, n = 5; 2021, n = 5; 2022, n = 24; 2023, n = 29; 2024, n = 38). We also observed a progressive rise of the proportion of CPE harboring a metallo-β-lactamase gene such as blaNDM or blaVIM (2020, 0.0%; 2021, 0.0%; 2022, 50.0%; 2023, 55.2%; 2024, 65.8%). Regarding the antimicrobial susceptibility, only 3.3% of all CPE isolates tested showed resistance to aztreonam/avibactam. In contrast, the resistance rates for cefiderocol and ceftazidime/avibactam amounted respectively to 12.8% and 53.9%. The increasing annual number of CPE at our hospital is associated with a rise of the proportion of metallo-β-lactamase-producing strains. The newly available antibiotic aztreonam/avibactam showed promising in vitro activity against CPE.","PeriodicalId":18701,"journal":{"name":"Microbial drug resistance","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbial drug resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10766294251384459","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

The primary purpose of this study was to assess the prevalence and the antimicrobial susceptibility rates of carbapenemase-producing Enterobacterales (CPE) in a German University Hospital during a 5-year period. From January 2020 to December 2024, all Enterobacterales detected were molecularly investigated for carbapenemases in every case of elevated minimum inhibitory concentration of ertapenem, meropenem, or imipenem. Subsequently, CPE were tested for susceptibility to reserve antibiotics. Overall, 101 CPE were identified. Most of the CPE strains harbored only one carbapenemase gene, such as bla_OXA-48 (n = 32, 31.6%), bla_NDM (n = 27, 26.7%), and bla_VIM (n = 14, 13.8%). The annual number of CPE detected increased during the observation period (2020, n = 5; 2021, n = 5; 2022, n = 24; 2023, n = 29; 2024, n = 38). We also observed a progressive rise of the proportion of CPE harboring a metallo-β-lactamase gene such as bla_NDM or bla_VIM (2020, 0.0%; 2021, 0.0%; 2022, 50.0%; 2023, 55.2%; 2024, 65.8%). Regarding the antimicrobial susceptibility, only 3.3% of all CPE isolates tested showed resistance to aztreonam/avibactam. In contrast, the resistance rates for cefiderocol and ceftazidime/avibactam amounted respectively to 12.8% and 53.9%. The increasing annual number of CPE at our hospital is associated with a rise of the proportion of metallo-β-lactamase-producing strains. The newly available antibiotic aztreonam/avibactam showed promising in vitro activity against CPE.

查看原文本刊更多论文

德国某大学医院产碳青霉烯酶肠杆菌5年临床流行病学及抗菌敏感性分析

本研究的主要目的是评估一家德国大学医院5年期间产碳青霉烯酶肠杆菌（CPE）的患病率和抗菌药敏率。从2020年1月至2024年12月，在厄他培南、美罗培南或亚胺培南最低抑制浓度升高的病例中，对检测到的所有肠杆菌进行碳青霉烯酶分子检测。随后，检测CPE对储备抗生素的敏感性。总共发现101例CPE。大多数CPE菌株仅携带一种碳青霉烯酶基因，如blaOXA-48 （n = 32, 31.6%）、blaNDM （n = 27, 26.7%）和blaVIM （n = 14, 13.8%）。观测期内CPE年检出数呈上升趋势（2020年，n = 5； 2021年，n = 5； 2022年，n = 24； 2023年，n = 29； 2024年，n = 38）。我们还观察到携带金属β-内酰胺酶基因（如blaNDM或blaVIM）的CPE比例逐渐上升（2020年，0.0%；2021年，0.0%；2022年，50.0%；2023年，55.2%；2024年，65.8%）。在抗菌药物敏感性方面，仅有3.3%的CPE分离株对氨曲南/阿维巴坦耐药。头孢地罗耐药率为12.8%，头孢他啶/阿维巴坦耐药率为53.9%。我院每年CPE病例数的增加与产金属β-内酰胺酶菌株比例的上升有关。新开发的抗生素aztreonam/avibactam具有良好的体外抗CPE活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Microbial drug resistance 医学-传染病学

CiteScore

6.00

自引率

3.80%

发文量

118

审稿时长

6-12 weeks

期刊介绍： Microbial Drug Resistance (MDR) is an international, peer-reviewed journal that covers the global spread and threat of multi-drug resistant clones of major pathogens that are widely documented in hospitals and the scientific community. The Journal addresses the serious challenges of trying to decipher the molecular mechanisms of drug resistance. MDR provides a multidisciplinary forum for peer-reviewed original publications as well as topical reviews and special reports. MDR coverage includes: Molecular biology of resistance mechanisms Virulence genes and disease Molecular epidemiology Drug design Infection control.